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JC polyomavirus mutants escape
antibody-mediated neutralization
Upasana Ray,1 Paola Cinque,2 Simonetta Gerevini,3 Valeria Longo,2 Adriano Lazzarin,2,4
Sven Schippling,5 Roland Martin,5 Christopher B. Buck,1* Diana V. Pastrana1*
JC polyomavirus (JCV) persistently infects the urinary tract of most adults. Under conditions of immune impair-
ment, JCV causes an opportunistic brain disease, progressive multifocal leukoencephalopathy (PML). JCV strains
found in the cerebrospinal fluid of PML patients contain distinctivemutations in surface loops of themajor capsid
protein, VP1. We hypothesized that VP1 mutations might allow the virus to evade antibody-mediated neutrali-
zation. Consistent with this hypothesis, neutralization serology revealed that plasma samples from PML patients
neutralizedwild-type JCV strains but failed to neutralize patient-cognate PML-mutant JCV strains. This contrasted
with serological results for healthy individuals, most of whom robustly cross-neutralized all tested JCV variants.
Mice administered a JCV virus-like particle (VLP) vaccine initially showed neutralizing “blind spots” (akin to those
observed in PML patients) that closed after booster immunization. A PML patient administered an experimental
JCV VLP vaccine likewise showedmarkedly increased neutralizing titer against her cognate PML-mutant JCV. The
results indicate that deficient humoral immunity is a common aspect of PML pathogenesis and that vaccination
may overcome this humoral deficiency. Thus, vaccination with JCV VLPs might prevent the development of PML.
INTRODUCTION
JC polyomavirus (JCV) is a nonenvelopedDNA virus that persistently
infects the urinary tract of most adults. Although JCV infection is not
known to be associated with overt clinical symptoms in healthy indi-
viduals, under conditions of immune dysfunction, such as HIV/AIDS,
the virus can cause an opportunistic brain disease, progressive multi-
focal leukoencephalopathy (PML) [reviewed in (1, 2)]. In recent years,
PML has also been increasingly observed in patients treated with newer
immunomodulatory drugs, such as the monoclonal antibody (mAb)
therapeutics natalizumab and rituximab (3). The mechanisms through
which a common, seemingly benign viral infection leads to lethal brain
disease in a minority of immunodeficient individuals remain unclear.
A recently approved enzyme-linked immunosorbent assay (ELISA)–
based test that detects serum antibodies specific for the JCV major
capsid protein VP1 is used in clinical practice for PML risk stratifi-
cation (4, 5). About 1% of JCV ELISA-seropositive individuals devel-
op PML during long-term natalizumab therapy (6, 7). It is unclear
why the JCV virion-specific antibodies detected in the ELISA fail to
prevent or limit the development of PML. A possible explanation is
that some or all of the antibodies detected in the ELISA fail to func-
tionally neutralize the infectivity of the virus (8).
A series of reports have shown that JCV variants found in the cere-
brospinal fluid (CSF) of PML patients carry a defined spectrum of
mutations in portions of VP1 that form exposed loops on the surface
of the assembled virion (9–13). Most PML-associated VP1 muta-
tions disrupt the ability of the virion to bind sialylated glycans, which
are thought to serve as infectious entry receptors for wild-type JCV
genotypes typically found in the urine. Maginnis and colleagues have
shown that PML-associated mutations disrupt the ability of JCV to
infect five transformed cell lines (14). The findings led the authors to
claim that PML-mutant JCV strains are globally noninfectious on all
cell types. In conflict with this claim, Kondo and colleagues have re-
cently shown that PML-mutant JCV strains readily infect primary
human oligodendrocytes, astrocytes, and glial progenitor cells, both
in culture and in intact brain tissue in vivo (15). In a commentary on
the findings of Kondo and colleagues, Haley and Atwood speculate
that primary glial cells support an alternative sialic acid–independent
infection pathway that is presumably absent in some cell lines (16). In-
deed, a variety of alternative entry factors have previously been proposed
for various polyomaviruses [reviewed in (17)]. Using JCV reporter vec-
tors (pseudoviruses), we identified several previously untested cell lines
that are, like the primary glial cells studied by Kondo and colleagues,
permissive for the infectious entry of both urine-derived wild-type
and PML-mutant JCV genotypes (see the Supplementary Materials).
The availability of cell lines permissive for transduction with pseudo-
viruses representing PML mutants provided us with a tractable method
for performing high-throughput serological analysis of JCV-neutralizing
antibodies. Here, we use this system to perform functional neutralization
serology to compare humoral immunity against JCV in healthy subjects
and in patients suffering from PML.
Virus-like particle (VLP) vaccines can be remarkably effective for
eliciting diverse, high-titer serum antibody responses capable of cross-
neutralizing closely related viral serotypes (18–20). Neutralization serol-
ogy was used to test the ability of an experimental VLP vaccine to elicit
antibody responses capable of cross-neutralizing PML-mutant JCVs in
a mouse model system and in a single case study of a PML patient ad-
ministered an experimental JCV VLP vaccine.
RESULTS
Neutralization testing of sera from healthy human subjects
JCV neutralization assays were used to screen a panel of sera from
96 healthy adult subjects. Sixty (63%) of the subjects neutralized a
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pseudovirus based on a urine-derived wild-type genotype 2A JCV with
a reciprocal 50% neutralizing titer (EC50) of greater than 100 (Fig. 1 and
table S1). This dilution was chosen as a seropositivity cutoff based on
past evidence that serum dilutions of less than 1:100 can have non-
specific neutralizing effects (perhaps due to the effects of serum factors
on the cultured cells) (21). With respect to the current study, it is im-
portant to note that, in healthy subjects, immunoglobulin G (IgG) an-
tibody concentrations in the CSF are typically 200- to 500-fold lower
than in the serum (22, 23). Experiments with intravenously admin-
istered mAb therapeutic agents indicate that serum IgG antibodies
chronically leak across the human blood-brain barrier and accumulate
in the central nervous system (CNS) at low levels (24). In this model,
IgG antibodies in the CSF essentially represent a lower-concentration
snapshot of antibodies found in the periphery. Thus, individuals with
a serumEC50 neutralizing titer of 100 would be expected to have poorly
neutralizing or nonneutralizing concentrations of antibodies in their
CNS. Our seroprevalence results using a neutralizing titer cutoff of
100 are concordant with a large body of previous seroprevalence studies
using JCV-1A VP1 ELISA methods [reviewed in (2)].
Although most of the samples that neutralized the 2A pseudovirus
also neutralized all other tested JCV genotypes with similar titers, a
minority of sera failed to detectably neutralize one or more PML-
mutant pseudoviruses (Fig. 1). Eleven of the 60 serum samples that
neutralized the 2A pseudovirus failed to neutralize the 2A-269F
pseudovirus. The S269Fmutation represents themost common variant
observed in the CSF of PML patients (11, 12). The results are consistent
with the idea that VP1 mutations found in the CSF of PML patients
could confer a selective advantage to the virus by allowing escape from
the apparently restricted spectrum of JCV-neutralizing antibodies ob-
served in a minority of JCV-seropositive individuals.
Longitudinal neutralization analysis of PML patient plasma
To investigate the idea that the unusual phenotype of having JCV neu-
tralization “blind spots” might be associated with an increased risk of
developing PML under conditions of T cell immunodeficiency, we per-
formed neutralization serology on a panel of plasma samples fromPML
patients. This work was confronted by two theoretical issues. First, PML
patientsmight exhibit a narrow neutralization blind spot encompassing
only the specific JCV VP1 sequence found in their CSF during PML.
Second, it seems conceivable that neutralization blind spots might close
during or after the development of PML. These considerations restricted
our focus to patients for whom plasma samples had been collected and
archived before the diagnosis of PML, and for whom the JCV sequences
found in their CSF during PML were known. Six PML patients met
these criteria. The underlying immunodeficiency in each of the six pa-
tients was HIV/AIDS, which was treated with combination antiretro-
viral therapy (table S2).
Pseudoviruses were constructed to represent the cognate mutant
VP1 sequence found in individual patients’ CSF during PML (table
S1). Pseudoviruses representing inferred wild-type VP1 sequences
were also produced. In some instances, the patient plasma samples
were tested against near-cognate pseudoviruses. As shown in Fig. 2,
fig. S4, and table S3, all six PML patients exhibited little or no neu-
tralization of their cognate PML-mutant pseudovirus at time points
before PML diagnosis, evenwhen therewas robust neutralization of the
wild-type pseudovirus. The results confirm the hypothesis that PML-
specific VP1 mutations can allow the virus to escape from antibody-
mediated neutralization.
Fig. 1. JCVneutralization serology (healthy adults). Serumsamples from
96 individual adult subjects (rows)were serially diluted and initially tested for
neutralization of a wild-type JCV-2A pseudovirus. Sixty serum samples that
detectably neutralized JCV-2A were tested against additional JCV pseudo-
viruses. Sera that failed to detectably neutralize JCV-2A were excluded from
further analysis and are not shown in the figure. The inverse log10 of the
calculated EC50 is indicated with a color code. EC50 values ≤2 (blue cells)
are considered neutralization-negative. For the precise VP1 sequence iden-
tity of JCV pseudovirus, see table S1.
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Patients who survived PML eventually developed broader antibody
responses capable of neutralizing their cognate PML-mutant pseudo-
virus. This suggests that at least some individuals with neutralization
blind spots are ultimately capable ofmounting broadly cross-neutralizing
antibody responses. In contrast to patients who survived PML, the three
patients with progressive (fatal) disease did not develop the ability to ro-
bustly neutralize their cognate mutant virus. Although this could simply
reflect the recovery of effective cell-mediated immunity (which would, in
turn, provide CD4+ T cell help for B cell responses), an important con-
clusion that can be drawn from the result is that individuals with JCV-
neutralizing blind spots are not intrinsically incapable ofmountingmore
broadly neutralizing antibody responses.
Remarkably, plasma frompatients 5029 and 5058 robustly neutral-
ized the 2A-269F pseudovirus at time points where there was poor
neutralization of the patient-cognate mutant virus, which carries the
S269F mutation in a slightly different genotypic background (fig. S4
and table S2). The results suggest that naturally occurring wild-type
genotypic variations outside the PML mutation “hotspots” can influ-
ence neutralization-escape phenotypes. This is consistent with the
observation that a few healthy subject sera that robustly neutralized
the wild-type 2A pseudovirus showed very low titers against the wild-
type 3B pseudovirus (Fig. 1). Together, the results illustrate the caveat
that it is essential to analyze the neutralization of the exact VP1
sequence(s) observed in any given subject.
Evaluation of JCV VLPs as vaccine immunogens in a
mouse model
To test the idea that a VP1 VLP-based vaccine against JCV might elicit
broadly neutralizing serum antibody responses, groups of mice were
given a single intramuscular dose of 720 ng of a monovalent VLP prep-
aration in alum. A single priming dose of VLP immunogen elicited
high-titer serum antibody responses capable of robustly neutralizing
the cognate pseudovirus (Fig. 3). Each set of primed mice failed to ro-
bustly cross-neutralize at least one noncognate pseudovirus type. This
result recapitulates the neutralization blind spot effects observed in
human subjects.
Mice were administered a booster dose of the same monovalent
VLP preparation. Sera from all boosted animals cross-neutralized all
tested JCV variants (fig. S5). This shows that blind spots can be closed
through prime-boost vaccination with a monovalent JCV VLP vaccine.
Overall, the wild-type 2A VLPs elicited the most uniformly robust
cross-neutralizing responses, suggesting that it is unnecessary (and per-
haps undesirable) to use PML-mutant VLP immunogens to elicit anti-
bodies capable of neutralizing PML-mutant pseudoviruses (25).
Case study of a PML patient administered an experimental
JCV vaccine
PML patient 5228 is a 75-year-old female with idiopathic CD4 lympho-
peniawhowas admitted at theDepartment of InfectiousDiseases of San
Raffaele Hospital (Milan, Italy) upon diagnosis with PML on 24 May
2012. Her case has not previously been reported. The patient’s clinical
condition deteriorated rapidly after admission and she became coma-
tose. In addition tomefloquine andmirtazapine, the patient was treated
with a previously reported vaccination protocol consisting of separate
administrations of interleukin-7 (IL-7) and JCV-1AVLPs combinedwith
imiquimod (26). As shown in Fig. 4 and table S3, vaccinationwas followed
by a roughly 100-fold increase in the patient’s neutralizing titer against her
cognate mutant virus. This confirms that PML patients are not intrinsi-
cally incapable of mounting new antibody responses capable of neutral-
izing their cognate JCV strain. After vaccination, patient 5228 showed an
extraordinarily high peak titer (25 million) against her inferred wild-
type JCV. This is particularly remarkable in the sense that the patient
Fig. 2. PML patient neutralization serology. Pre- and post-PML plasma
samples from six patients were tested for neutralization of cognate (or
near-cognate) wild-type (WT) and PML-mutant pseudoviruses. Specifically,
patient 5029 was tested against viruses 5029w (cognate WT, blue) and
5029m (cognate mutant, red); 5031: 5031w/5031mb; 5040: 2A/5040m;
5053: 5053w/5053m; 5058: 2A/5147m; 5147: 5147w/5147m (see table S1).
Testing of PML patient sera against additional pseudoviruses is shown
in fig. S4. Patients whose disease progressed (left column) are indicated
with (P), and patients who survived (right column) are indicated with (S).
Dominant PML-associated mutations observed in each patient’s CSF are
indicated. Y axes indicate neutralizing EC50. Error bars represent SEM for
data from three independent experimental replicates, two of which were
performed with blinding. Arrows below the x axes indicate the date of
onset of PML symptoms. Date format is month/day/year.
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was suffering from intermittent lymphopenia at the time of vaccination
(fig. S6). Although it is tempting to speculate that the JCV VLP com-
ponent of the treatment was a primary factor in induction of a potent
humoral immune response, we note that a previous case study of a PML
patient administered recombinant IL-7 alone (without JCV VLPs) also
showed increasing anti-JCV antibody titers, including a pronounced IgM
response (27). This suggests that improved CD4 T cell function and
“auto-inoculation” with PML lesion–derived virions could have played
a significant role in the response. Increases in patient 5228’s JCV-
neutralizing titer preceded a gradual fall in JCV viremia (Fig. 4 and table
S5) andanarrest ofPMLlesionprogression
(Fig. 5). It is uncertain whether there was a
causal relationship between the improved
JCV-neutralizing antibody response and
the resolution of disease progression.
DISCUSSION
Our results indicate that a minority of
healthy JCV-seropositive subjects are de-
ficient in serum antibodies capable of
neutralizing JCVs carrying VP1 muta-
tions associated with PML. A simple ex-
planation for this finding is that some
individuals may have an unusually low
diversity of plasma cells secreting effec-
tively neutralizing antibodies, such that
single point mutations in VP1 can allow
the virus to evade neutralization. This find-
ing is consistentwith past observations in
murine viral challenge systems (28), and
wehave recently reported a similar scenar-
io for BKV (a close relative of JCV) (29).
Neutralization-escape mutations would presumably increase the fitness
of the virus under circumstances where T cell–mediated immunity in
the CNS is impaired, and antibody-mediated neutralization therefore
serves as a last line of defense against neuropathic JCV replication.
The idea that humoral vulnerability is a key element of PML patho-
genesis is supported by the observation that all six PML patients we
studied displayed neutralization blind spots before disease onset.
At present, there are no antiviral agents known to be effective for the
treatment of JCV disease, and reversal of immune dysfunction remains
the only approach of proven utility for the treatment of PML. Immune
reconstitution treatments are not always timely or successful and, even
if they are successful, sometimes lead to immune reconstitution inflam-
matory syndrome, which can be lethal (30). VLP-based vaccines against
other viral families have been highly successful in humans (31, 32). In
particular, VLP-based vaccines against human papillomaviruses (which
share key structural features with polyomaviruses) elicit remarkably po-
tent, diverse, and long-lasting neutralizing antibody responses [re-
viewed in (20)]. Our testing of experimental JCV VLP immunogens
demonstrates that high-titer serum antibody responses capable of
broadly cross-neutralizing PML-mutant JCVs can be elicited by
prime-boost vaccination with VLPs representing a single wild-type
JCV genotype. Because antibodies are present at much lower levels in
the CNS (23, 24), the apparently high immunogenic potency of JCV
VLP immunogens could be important for induction of protective levels
of JCV-neutralizing antibodies in the brain parenchyma. Together, the
results suggest that a prophylactic JCVVLP vaccine could serve to boost
and broaden humoral immunity against JCV and thus protect at-risk
individuals against the development of PML.
Although the widespread availability of combination antiretro-
viral therapy has led to a marked decrease in the incidence of AIDS,
treatment failure and/or lack of compliance with antiretroviral dos-
ing schedules remain long-term risks for HIV-infected individuals.
The availability of a preventive vaccine against PML could thus be
of potential benefit for people living with HIV.
Fig. 3. Preclinical evaluation of a candidate JCV VLP vaccine. Mice were given an intramuscular
injection of VLPs based on the JCV genotype indicated in each row label. Four weeks later, sera from
the mice were tested for neutralization of various pseudoviruses indicated in column labels. Numerical
values represent EC50 neutralizing titers. Error represents SD for independent neutralization assays of
sera from five replicate mice. Preimmune sera were nonneutralizing at a 1:100 dilution.
Fig. 4. JCV-neutralizing titers after vaccination of PML patient 5228.
Patient 5228was administered JCVVLPs subcutaneously at three timepoints
(downward purple triangles). Recombinant IL-7 was also administered for
two cycles each consisting of a subcutaneous weekly dose of 10 mg/kg
(upward green triangles). The patient’s neutralizing titer against her cognate
PML-mutant JCV (red squares) or inferred WT JCV (blue circles) was moni-
tored over time. JCV load in the patient’s plasma (gray dots) was alsomonitored
over time. See the Supplementary Materials for additional patient details.
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At present, treatment of multiple sclerosis patients with the highly
effective mAb therapeutic natalizumab is generally time-limited be-
cause of the progressively increasing risk of PML side effects (2).
The utility of the drug rituximab for treating rheumatoid arthritis is
likewise limited by PML side effects. Efalizumab, an immunomodula-
tory mAb previously used for the treatment of psoriasis, was with-
drawn from market because of PML side effects. Perhaps a dozen
other immunomodulatory agents that are either in development or
on the market are potentially associated with rare PML side effects.
Thus, the availability of safe and effective measures for preventing
PML could significantly increase the overall safety profiles of therapies
for a wide variety of autoimmune diseases and lymphoid cancers. This
would be particularly true for immunomodulatory therapies, such as
natalizumab, that are compatible with vaccination (33).
A limitation of our study is the availability of only a small popu-
lation of PML patients with appropriate longitudinal samples. Thus,
it remains unclear whether neutralizing blind spots are a universal
feature of PML development or whether, in some patients, the disease
develops despite the presence of an effective humoral response. Like-
wise, although the single case study of patient 5228 is consistent with
the possibility that IL-7/JCV VLP administration was a factor in arrest
of PML progression, the fact that other patients, including another pa-
tient administered IL-7withoutVLPs (27, 34), sometimes spontaneous-
ly recover leaves the question of whether
JCVVLPswould be a useful therapeutic in-
tervention for the treatmentofPMLunclear.
An additional limitation of the study
is that we did not have access to paired
CSF samples for healthy subjects and only
sporadic CSF samples from some of the
PML patients. In the future, it will be im-
portant to test the prediction that serum
JCV-neutralizing antibody responses es-
sentially represent a 200- to 500-fold higher
titer than would typically be observed in
CSF (22–24). Itwill be important to address
this question using passive transfer of anti-
bodies (or bone marrow plasma cells) in
the new murine PML model reported by
Kondo and colleagues (15). Such experi-
ments could test the prediction that broad-
ly cross-neutralizing antibodies could
protect mice against PML when admin-
istered at high doses, whereas lower doses
of “blind spot” polyclonal antibodies (for
example, frommice given a single priming
dose of JCV-3BVLPs)might drive the evo-
lution of the commonL55F and S269F es-
cape mutations.
MATERIALS AND METHODS
Study design
A set of 96 previously characterized (21)
healthy human sera were screened for
neutralization of wild-type JCV-2A pseu-
dovirus. The JCV-2A–neutralizing sera
were then tested against diverse range of JCV variants. Testing of
healthy subject sera did not use blinding. Serum samples from six
PML patients for whom CSF JCV sequences were known were initially
tested against the indicated cognate pseudoviruses without blinding.
Samples from the six PML patients were then randomized and retested
in two independent additional experiments in a blinded fashion. Neu-
tralization serology for patient 5228 (who was vaccinated with JCV
VLPs) was likewise initially performed without blinding followed by
two blinded repeats. Experiments with mice arbitrarily used five
animals per group. Serological analysis of mice was performed without
blinding.
Pseudovirus production
Pseudovirions were produced using previously describedmethods, with
minor modifications (21, 35). Briefly, Gaussia luciferase reporter genes
were packaged into pseudovirions in 293TT cells transiently transfected
with JCV VP1/2/3 expression plasmids. The resulting pseudovirions
were purified over OptiPrep gradients. Additional methodological de-
tails are presented in the Supplementary Materials.
Sera
Healthy subject sera were purchased from Equitech Bio Inc. and Inno-
vative Research Inc. (21, 29, 36). Ethical assurances are provided on the
Fig. 5. Evolution of PML lesions by magnetic resonance imaging in patient 5228. The patient was
initially diagnosedwith PML on 24May 2012. The date of each scan is indicated along the top of the figure.
Axial fluid-attenuated inversion recovery (FLAIR, row a), diffusion-weighted imaging (DWI, row b), and
FLAIR-DWI merged images (row c) show the evolution of PML lesions. Row a: The first image on the left
(July 2012) shows a high signal intensity lesion of the right parieto-occipital white matter extending con-
tralaterally through the corpus callosum; another focus is present in the left subcortical temporal region.
Subsequent examinations showed evolution of the signal alteration with progressive rapid extension of
the lesions to the entire white matter bilaterally. In September 2012, the white matter was completely
occupied by lesional and atrophic processes and enlargements of the ventricles and cortical sulci began
to appear. The last examinations (January andMarch 2013) show progression of atrophy. Row b: Axial DWI
images show the evolution of the hyperintense signal alterations corresponding to the front of progres-
sion of PML lesions (red arrows). The signal alteration is substantially reduced starting from November
2012 and is no longer visible at the March 2013 examination, implying lesion stabilization. Row c: Merged
FLAIR and DWI sequences show, in yellow (black arrows), the initial fronts of advance of PML lesions and
their regression over time.
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suppliers’ Web sites. Samples from PML patients were collected either
for diagnostic purposes or as part of internal research protocols ap-
proved by the Ethical Committee of San Raffaele Hospital, Milan.Writ-
ten informed consent to use of samples and clinical information was
given by patients who were still alive at the time of the start of the study.
Permission from the Ethical Committee was given for the use of
samples and clinical information from patients who were deceased.
Serumandplasma sampleswere heat-inactivated at 56°C for 30min,
followed by brief centrifugation to sediment any aggregated material.
For samples from healthy adults, serum IgG antibodies were then puri-
fied out of the serum samples usingMelon Gel (Pierce) resin according
to the manufacturer’s instructions. Plasma samples from PML patients
and mice were not subjected to Melon Gel purification.
Neutralization assays
Generation and use of ART cells [an ovarian cancer line (37, 38)] and
SFT cells [a gliosarcoma line (39)] for neutralization assays have been
described previously (29). In initial validation experiments, comparable
JCVneutralization resultswere observedusing either cell line (fig. S3) (39).
Neutralization serology studies used ART cells with the dose of VP1
specified in table S1.
Preclinical VLP vaccine
Animal experiments were performed at the National Cancer Institute fa-
cilities under the approval of the Animal Care and Use Committee and
according to the guidelines of the Association for Assessment and Ac-
creditation of Laboratory Animal Care International. Procedures were
carried out in accordancewith the eighth editionof theNational Research
Council of the National Academies’ Guide for the Care and Use of Lab-
oratory Animals. Female BALB/cAnNCr mice were subjected to intra-
muscular immunization with 720 ng of JCV VLPs (VP1 only) mixed
with 0.2%of aluminumhydroxide (alum, InvivoGen)with a total volume
of 50 ml. Five mice were immunized per JCVVLP type. Onemonth after
the single priming dose of VLPs, plasma samples were collected by
submandibular bleed into Microtainer lithium-heparin tubes (BD). The
mice were then boosted with the same JCV VLP type intramuscularly in
alum. Serum samples were collected 1 month after the booster dose.
Vaccination case study
Ethical approval for compassionate administration of the IL-7/VLP com-
bination treatment was provided by the Ethical Committee of San Raf-
faele Hospital. The family of patient 5228 gave written informed consent
for the collection and use of research samples and for the experimental
administration of the IL-7/JCV VLP vaccine. Recombinant human IL-7
was given subcutaneously at 10 mg/kg on 9, 16, and 23 June 2012 (first
cycle) and on 25 October, 2 November, and 9 November 2012 (second
cycle). Subcutaneous injections of 1 mg of VLPs composed of JCV-1A
VP1 were performed on 28 June, 6 July, and 8 August 2012. The VLP
preparationwas the same as the one previously administered to twoother
patients whose cases were described in a recent report by Sospedra and
colleagues (26). Imiquimod cream (5%, Aldara, Meda Pharmaceuticals)
was applied as a vaccine adjuvant topically at the injection site. The treat-
ments appeared to be well tolerated. Additional clinical details for patient
5228 are provided in the Supplementary Materials.
Statistical analyses
The neutralization titers were calculated in Prism (GraphPad) using
nonlinear regression analyses. A sigmoidal dose-response equation
(variable slope) (four-parameter logistic equation) was used with top
and bottom values constrained based on “no antibody” and “no virus”
controls, respectively.
SUPPLEMENTARY MATERIALS
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